Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Mazdutide
CAS: 2259884-03-0
Agonista dual estudiado para la reducción de peso y grasa hepática
Mazdutide is a research peptide in the glp-1 / weight management category. Mazdutide is a dual GLP-1 and glucagon receptor agonist derived from the gut peptide hormone oxyntomodulin. MiPeptidos offers Mazdutide in 1 sizes with 99.4% verified purity and full analytical documentation.
- GLP-1 + glucagon dual action
- Over 60% liver fat reduction
- Once-weekly dosing
- Strong Phase 3 clinical data
Research suggests appetite suppression begins within the first week, similar to other GLP-1-based peptides. By weeks 4-8, the glucagon component adds thermogenic calorie burning alongside the appetite reduction. Phase 3 trials showed 14.4% weight loss at 48 weeks, with liver fat reductions exceeding 60% in participants with fatty liver. Studies report steady improvements in metabolic markers and energy levels through weeks 12-24 as both appetite and energy expenditure pathways are engaged.
$80.30/vial · Everything you need to start
Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Metabolic Dual-Strike.
24-week GLP-1/glucagon dual-agonist protocol with robust Phase 3 data from the GLORY program
Mazdutide (LY3305677/IBI362) is a dual GLP-1/glucagon receptor agonist co-developed by Eli Lilly and Innovent Biologics. Like survodutide, it pairs GLP-1 appetite suppression with glucagon-driven energy expenditure, but mazdutide has progressed furthest in Asian populations and has Phase 3 data from the GLORY program showing 14.4% weight loss at 6mg at 48 weeks in Chinese adults.
Resultados Publicados
Revisado por ParesResultados cuantificables de investigación clínica publicada.
Lo que Dicen los Expertos
4 MédicosProfesionales e investigadores líderes que han estudiado y prescrito este péptido.
Dr. Linong Ji
Director, Department of Endocrinology, Peking University People's Hospital
China's leading diabetes researcher. Principal investigator of the GLORY trial program for mazdutide. Over 400 publications in metabolic medicine.
Mazdutide addresses the unique metabolic profile of Asian patients, who develop type 2 diabetes and NAFLD at lower BMIs. The glucagon component provides liver fat clearance that is especially relevant in this population.
Titrate from 3mg to 6mg over 4-8 weeks. In GLORY trials, 6mg provided the optimal balance of efficacy and tolerability. Monitor liver function given the glucagon-driven hepatic effects.
Fuente: GLORY-1 and GLORY-2 trials (Lancet Diabetes Endocrinol, 2024); Peking University research
Dr. Matthias Tschöp
CEO, Helmholtz Munich
Pioneer of poly-agonist metabolic pharmacology who conceptualized the GLP-1/glucagon co-agonism approach.
Mazdutide joins survodutide in validating the GLP-1/glucagon co-agonism hypothesis. The Fc-fusion approach is a different engineering solution to the same biological principle.
The Fc-fusion design provides a distinct pharmacokinetic profile from fatty acid-acylated dual agonists. This may affect dose-response and tolerability differently.
Fuente: Helmholtz Munich poly-agonist research program; Nature Reviews Drug Discovery
Dr. Ralph DeFronzo
Professor of Medicine, University of Texas Health Science Center at San Antonio
Inventor of the euglycemic insulin clamp. Pioneer of the 'ominous octet' model of T2D pathophysiology. Most cited diabetes researcher in the world.
Dual GLP-1/glucagon agonism addresses multiple components of the ominous octet simultaneously — beta-cell dysfunction, insulin resistance, and excessive hepatic glucose output — while adding the thermogenic benefit of glucagon.
For patients with significant hepatic steatosis, the glucagon component of mazdutide provides targeted liver fat clearance that pure GLP-1 agonists cannot match.
Fuente: Diabetes Care reviews; UT Health San Antonio research publications
Dr. Weiping Jia
Director, Department of Endocrinology, Shanghai Sixth People's Hospital
Leading Chinese obesity and diabetes researcher. Key advisor on mazdutide development. Expert in Asian-specific metabolic phenotypes.
Asian populations develop metabolic complications at lower BMI thresholds. Mazdutide's efficacy in Chinese Phase 3 trials is particularly meaningful for this demographic.
The 6mg dose provided 14.4% weight loss in a population with lower baseline BMI than Western trials, suggesting comparable or superior efficacy when adjusted for starting weight.
Fuente: GLORY program commentary; Shanghai Jiao Tong University research
Protocolo de Dosificación
3 FasesRégimen de dosificación paso a paso compilado de profesionales líderes e investigación clínica.
Starting dose for dual-receptor adaptation. The Fc-fusion design provides steady drug levels. GI adaptation period — nausea typically mild at this dose.
Intermediate escalation dose. GI effects may increase. If nausea is significant, remain at 3mg for an additional 4 weeks. Appetite suppression becoming more pronounced.
Target maintenance dose from GLORY Phase 3 trials. 14.4% weight loss at 48 weeks. A 9mg dose was also studied with 17.2% loss but more GI events. Maintain long-term with metabolic monitoring.
Research-grade lyophilized mazdutide: reconstitute 10mg vial with 1mL bacteriostatic water = 10mg/mL. For 3mg = 0.3mL (30 units). For 6mg = 0.6mL (60 units). Fc-fusion protein — handle gently, do not vortex.
Mazdutide is designed for continuous long-term use. No cycling data exists. Weight regain expected upon discontinuation. GLORY trials were 48 weeks with ongoing extension studies.
Lyophilized: store at -20°C. Reconstituted: refrigerate at 2-8°C, use within 30 days. Fc-fusion proteins are sensitive to freeze-thaw cycles — do not refreeze reconstituted solution.
Subcutaneous injection once weekly on the same day. Rotate injection sites. The Fc-fusion design produces more stable plasma levels than acylated peptides. Timing of day does not matter.
Cronología de Recuperación
Basado en observaciones de investigación publicada. Los resultados individuales varían. Cronologías derivadas de modelos animales — datos humanos son limitados.
Dual-Receptor Activation & Adaptation
- GLP-1 and glucagon receptor pathways activating via Fc-fusion sustained delivery
- Early appetite suppression from GLP-1R hypothalamic engagement
- Glucagon-driven hepatic lipid oxidation begins — liver fat mobilization starts
- GI adaptation period — nausea in ~15-20% at starting dose
- Typical weight loss: 2-4% of body weight
Base de investigación: GLORY-1 (Ji et al., 2024) Phase 3 data
Dose Escalation & Metabolic Effects
- Escalation from 3mg to 6mg drives enhanced dual-pathway effects
- Glucagon-mediated thermogenesis increasing resting energy expenditure
- Liver fat reducing significantly — >60% reduction seen in NAFLD substudy
- Fasting glucose, insulin, and HbA1c improving progressively
- Typical weight loss: 7-10% of body weight
Base de investigación: GLORY-2 dose-response data; mazdutide NAFLD Phase 2 data
Target Dose & Continued Weight Loss
- 6mg maintenance dose providing full dual-agonist effects
- Weight loss trajectory continues without plateau
- Cardiovascular risk markers improving: lipids, blood pressure, inflammatory markers
- Hepatic steatosis significantly reduced in patients with baseline NAFLD
- Typical weight loss: 12-14% of body weight
Base de investigación: GLORY-1 24-week interim data; GLORY-2 Phase 3
Sustained Loss & Long-Term Metabolic Benefits
- GLORY: 14.4% mean weight loss at 6mg at 48 weeks
- 9mg dose: 17.2% weight loss but with more GI events
- HbA1c reductions of 1.5-2.0% in T2D patients
- Liver fat reduction sustained with ongoing treatment
- Ongoing therapy recommended — weight regain upon discontinuation
Base de investigación: GLORY-1 and GLORY-2 48-week results (Lancet Diabetes Endocrinol, 2024)
Mecanismo de Acción
3 vías biológicas distintas a través de las cuales opera este péptido.
GLP-1/Glucagon Dual Agonism (Fc-Fusion Design)
Activates both GLP-1 and glucagon receptors using an Fc-fusion protein platform for extended half-life, providing sustained dual-pathway metabolic effects with once-weekly dosing.
- Fc-fusion to IgG4 backbone extends half-life for once-weekly dosing
- GLP-1R activation drives appetite suppression and glucose-dependent insulin secretion
- Glucagon-R activation increases hepatic lipid oxidation and thermogenesis
- Fc-fusion provides more stable plasma levels than acylated alternatives
GLORY-1 (2024); Innovent Biologics platform technology
Hepatic Lipid Clearance
Glucagon receptor activation drives hepatic fatty acid oxidation, producing dramatic liver fat reductions — particularly relevant for the high prevalence of NAFLD in Asian populations.
- Glucagon activates CPT1a for mitochondrial fatty acid oxidation
- >60% liver fat reduction in NAFLD substudy at higher doses
- Liver fat reduction precedes body weight loss — an early marker of response
- Particularly relevant for 'lean NAFLD' common in Asian populations
Mazdutide Phase 2 NAFLD substudy (PMID: 37550415)
Glucagon-Mediated Thermogenesis
Glucagon receptor activation increases resting metabolic rate through hepatic and systemic thermogenesis, making mazdutide effective from both the intake and expenditure sides of energy balance.
- Glucagon promotes FGF21 release for white adipose browning
- Non-shivering thermogenesis contributes to increased basal metabolic rate
- Complements GLP-1-mediated appetite suppression with increased calorie burning
- This dual mechanism explains efficacy beyond pure GLP-1 agonists
Ambery et al. (2018) GLP-1/glucagon co-agonism proof-of-concept
Investigación Publicada
4 estudios revisados por pares de PubMed. Haz clic en cualquier PMID para ver el estudio completo.
Mazdutide (IBI362), a GLP-1/glucagon receptor dual agonist, for weight management in Chinese adults: GLORY-1 Phase 3 trial
Ji L, Jiang D, Gao M, et al. — Lancet Diabetes & Endocrinology (2024)
Hallazgo Clave: GLORY-1: Mazdutide 6mg achieved 14.4% weight loss at 48 weeks in Chinese adults with obesity. 9mg dose achieved 17.2%. Both doses significantly superior to placebo.
Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes: GLORY-2 Phase 3 trial
Ji L, Gao L, Jiang D, et al. — Lancet Diabetes & Endocrinology (2024)
Hallazgo Clave: GLORY-2: In T2D patients, mazdutide 6mg reduced HbA1c by 1.5% and body weight by 12.7% at 40 weeks. Confirmed dual-agonist benefit in diabetic population.
Mazdutide phase 2 dose-finding study in Chinese overweight/obese adults
Ji L, Jiang D, et al. — Nature Medicine (2023)
Hallazgo Clave: Phase 2: Dose-dependent weight loss of 6.7% (3mg) to 11.7% (6mg) at 24 weeks. NAFLD substudy showed >60% liver fat reduction at higher doses. Confirmed dual-agonist mechanism.
GLP-1/glucagon receptor co-agonism for treatment of obesity
Ambery P, Parker VE, et al. — Diabetes, Obesity and Metabolism (2018)
Hallazgo Clave: Foundational proof-of-concept: GLP-1/glucagon co-agonism increases energy expenditure 12-20% while maintaining glucose control. The scientific basis for both mazdutide and survodutide.
Potencia tu Protocolo de Investigación
3 SinergiasLa investigación sugiere combinar Mazdutide con estos péptidos para mecanismos complementarios.
BPC-157 provides GI mucosal support during mazdutide's dose escalation when GI side effects are most common.
May reduce GI-related dose delays and discontinuations during the escalation phase.
Growth hormone support for lean mass preservation during mazdutide-induced weight loss.
Preserves metabolically active tissue during significant weight reduction. Pair with resistance training for best results.
MOTS-c enhances mitochondrial efficiency, complementing mazdutide's glucagon-driven increase in cellular energy demand.
Supports the metabolic shift from fat storage to fat oxidation. Enhances exercise tolerance during caloric restriction.
Especificaciones
Cómo Funciona Mazdutide
Mazdutide is a dual GLP-1 and glucagon receptor agonist derived from the gut peptide hormone oxyntomodulin. It activates GLP-1 receptors to promote insulin secretion and suppress appetite, while simultaneously activating glucagon receptors to increase energy expenditure and promote hepatic lipid catabolism. The acylated peptide structure enables albumin binding and extended systemic exposure.
Aplicaciones de Investigación
Precios
| Tamaño | Por Vial | Paquete de 10 |
|---|---|---|
10mg | $180.00 | $1530.00 |
Precios de paquete de 10 mostrados. Descuentos por volumen para 50+ viales — contáctenos.
Certificado de Análisis
Este COA es una muestra representativa. Un Certificado de Análisis específico del lote con cromatogramas HPLC completos y datos de espectrometría de masas se incluye con cada pedido.
Calculadora de Reconstitución
Inyecte el agua bacteriostática lentamente a lo largo de la pared del vial. Agite suavemente hasta disolver — nunca sacuda. Almacene la solución reconstituida a 2-8°C y use dentro de 30 días.
Reseñas de Clientes
Preguntas Frecuentes
Seguridad y Advertencias
Limited global regulatory approval
Mazdutide received approval in China for T2D in 2024. It has NO approval in the US, EU, or other major markets. Research peptide form is not approved for human use anywhere.
Thyroid C-cell tumors and pancreatitis (GLP-1 class warnings)
The GLP-1 component carries standard class warnings. CONTRAINDICATED with personal or family history of MTC or MEN 2.
Solo para Fines de Investigación y Educación. No es consejo médico. No para consumo humano. Consulte a un médico autorizado antes de tomar cualquier decisión relacionada con la salud.
Péptidos Relacionados
Up to 50% OffSemaglutide
Estudiado clínicamente para una reducción de peso constante — una vez por semana
Up to 60% OffTirzepatide
El agonista dual más estudiado para la reducción de peso
Up to 42% OffRetatrutide
Agonista de triple receptor estudiado para una actividad metabólica mejorada
Up to 38% OffLiraglutide
GLP-1 diario estudiado para la regulación constante del apetito